Call: 08045479200
Send Inquiry
Zolinza Vorinostat
Product Details:
- Dosage Form Capsules
- Salt Composition Vorinostat
- Indication Treatment of cutaneous manifestations in patients with cutaneous T-cell lymphoma (CTCL) who have progressive, persistent, or recurrent disease on or following two systemic therapies
- Enzyme Types Histone deacetylase inhibitor (not an enzyme, but a class of enzyme inhibitor)
- Feature Oral histone deacetylase (HDAC) inhibitor for advanced CTCL
- Ingredients Each capsule contains 100 mg vorinostat
- Application Pharmaceutical/Oncology
- Click to View more
X
Zolinza Vorinostat Product Specifications
- Vorinostat
- White to off-white powder-filled capsules
- Capsules
- Histone deacetylase inhibitor (not an enzyme, but a class of enzyme inhibitor)
- 2 years from date of manufacture
- Store at 20C to 25C (68F to 77F), excursions permitted to 15C to 30C (59F to 86F)
- Pharmaceutical/Oncology
- Each capsule contains 100 mg vorinostat
- Treatment of cutaneous manifestations in patients with cutaneous T-cell lymphoma (CTCL) who have progressive, persistent, or recurrent disease on or following two systemic therapies
- Oral histone deacetylase (HDAC) inhibitor for advanced CTCL
- Odorless
- Hypersensitivity to Vorinostat
- Prescription only medication
- 100mg
- 149647-78-9
- For use only under medical supervision
- C14H20N2O3
- Bottle of 120 Capsules
- L01XX43
- US FDA Approved for CTCL
- Oral
- Fatigue, nausea, diarrhea, thrombocytopenia, anemia
Zolinza Vorinostat Trade Information
- 500 Per Month
- 7 Days
- Asia, Australia, Central America, North America, South America, Eastern Europe, Western Europe, Middle East, Africa
- All India
Product Description
Since our establishment in 1991, we have aimed to reach on top of the industry by offering Zolinza Vorinostat. It is used to treat skin problems caused by cutaneous T-cell lymphoma. Our skilled agents procure this drug from the certified vendors of the market. The drug is usually given after other treatments have been tried without successful treatment. Clients can avail Zolinza Vorinostat in different strength as per their requirements. We offer the drug at pocket friendly prices.
Features:
- Prevents the growth of cancer
- No fatigue after consuming
- Accurate composition
A Proven Oral Therapy for Advanced CTCL
Zolinza offers a targeted approach to managing advanced cutaneous T-cell lymphoma. As an FDA-approved oral histone deacetylase inhibitor, it is specifically designed for patients who have not responded to prior systemic treatments. Its oral administration allows for greater convenience compared to intravenous therapies, supporting home-based cancer care under medical guidance.
Patient-Friendly Dosage and Storage
Each Zolinza capsule delivers a precise 100mg dose of vorinostat in an easy-to-swallow format. Bottled with 120 capsules, it offers a streamlined regimen for patients and healthcare providers alike. The product should be stored at 20C to 25C, with permissible excursions between 15C and 30C, ensuring optimal stability throughout its 2-year shelf life.
FAQs of Zolinza Vorinostat:
Q: How should Zolinza Vorinostat capsules be taken?
A: Zolinza should be taken orally exactly as prescribed by your healthcare provider. The prescribed dose should not be adjusted or skipped without consulting your doctor, and capsules must be swallowed whole with water.Q: What is Zolinza Vorinostat used for?
A: Zolinza is indicated for the treatment of cutaneous manifestations in patients with cutaneous T-cell lymphoma (CTCL) who have progressive, persistent, or recurrent disease after at least two systemic therapies.Q: When is Zolinza considered appropriate for use?
A: Zolinza is considered for patients with advanced CTCL who have not responded adequately to two prior systemic treatments, and only under strict medical supervision due to its specific therapeutic profile and side effects.Q: Where should Zolinza capsules be stored?
A: Zolinza capsules should be kept at room temperature between 20C and 25C (68F to 77F), with acceptable short-term ranges from 15C to 30C (59F to 86F). Ensure the bottle is tightly closed and stored away from excess heat and moisture.Q: What benefits does Zolinza offer to oncology patients?
A: Zolinza provides a non-invasive, oral treatment option for advanced CTCL, which can be taken at home. Its mechanism as an HDAC inhibitor may slow disease progression when previous treatments have failed, improving patient outcomes under supervision.Q: Are there any side effects or contraindications to be aware of with Zolinza?
A: Common side effects include fatigue, nausea, diarrhea, thrombocytopenia, and anemia. Zolinza is contraindicated in individuals with hypersensitivity to vorinostat. Always use only under the direction of a qualified healthcare professional.Tell us about your requirement
Price:
Quantity
Select Unit
- 50
- 100
- 200
- 250
- 500
- 1000+
Additional detail
Mobile number
Email
Other Products in 'Anti Cancer Capsules' category
We Mainly Deal in International Market.
Contact Details
PRISSM PHARMA
GST : 27AARFP5752B1Z1
- 12/B, Thacker Industrial Estate, N. M. Joshi Marg, Lower Parel (E),Mumbai - 400011, Maharashtra, India
- Phone :08045479200
Send Inquiry
Developed and Managed by Infocom Network Private Limited.
